Tetsuya Fujimori

Direttore/Membro del Consiglio presso Cenegenics Japan KK

55 anni

Health Technology

Consumer Services

Profilo

Tetsuya Fujimori is currently the Representative Director at Cenegenics Japan KK since 2020.
Prior to this, he worked as an Independent Outside Director at tella, Inc. Mr. Fujimori completed his undergraduate degree from Osaka City University in 1995.

Posizioni attive di Tetsuya Fujimori

Società	Posizione	Inizio
Cenegenics Japan KK Cenegenics Japan KK Medical SpecialtiesHealth Technology Cenegenics Japan KK engages in the advanced medical support business using genes, cells, and tissues. The company was founded on March 23, 2020 and is headquartered in Tokyo, Japan.	Direttore/Membro del Consiglio	01/03/2020

Tutte le posizioni attive di Tetsuya Fujimori

Precedenti posizioni note di Tetsuya Fujimori

Società	Posizione	Fine
TELLA, INC.	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Tetsuya Fujimori

Formazione di Tetsuya Fujimori

Osaka City University

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Tetsuya Fujimori

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Cenegenics Japan KK Cenegenics Japan KK Medical SpecialtiesHealth Technology Cenegenics Japan KK engages in the advanced medical support business using genes, cells, and tissues. The company was founded on March 23, 2020 and is headquartered in Tokyo, Japan.	Health Technology
tella, Inc. tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan.	Health Technology